Veradigm fails to find a buyer, moves to operational review
The health tech company formerly known as Allscripts, still reeling from failing to fix its financial reports, will have to go it alone.
Veradigm ends exploration of strategic alternatives without deal
Veradigm (MDRX) announced that its board of directors completed its previously announced review of strategic alternatives. “Throughout the
Veradigm Concludes Exploration of Strategic Alternatives and Announces Operational Review
Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, announced today that the Veradigm Board of Directors (the “
23andMe is exploring strategic alternatives, looking to raise capital
23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter results that showed an 8% drop in consumer services revenue year over year. 23andMe said it will "need additional liquidity" to fund its operations, and it is looking to raise additional capital.
23andMe Special Committee Announces Exploration of Strategic Alternatives
The Board of Directors of 23andMe previously formed the Special Committee, which is comprised of independent directors, to review strategic alternatives that may be available to 23andMe. The Special Committee has engaged Moelis & Company LLC as its financial advisor and Goodwin Procter LLP as its legal advisor.
Veradigm ends strategic review after no firm bids
Veradigm (OTC:MDRX) said that it's ending a strategic review after it received no firm proposals in its process. The electronic medical records firm disclosed that five bidders made preliminary, non-biding indications of interest,
Hosted on MSN12d
NGVT to Evaluate Strategic Alternatives for Industrial Specialties
Ingevity Corporation NGVT recently announced plans to explore strategic alternatives for its Performance Chemicals Industrial ...
WILLOW ANNOUNCES INITIATION OF STRATEGIC REVIEW PROCESS
Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on ...
FiercePharma5d
No deal: Sage rejects Biogen's buyout offer, scouts for strategic alternatives
After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on ...
BioSpace5d
Sage Rejects Biogen’s Unsolicited Offer, Will Seek Strategic Alternatives
Following a lawsuit filed last week, Sage has officially rejected Biogen’s unsolicited buyout offer, which valued the ...
Hosted on MSN19d
S&W Seed rises after starting review of strategic alternatives
S &W Seed (NASDAQ:SANW) +4.8% post-market Monday after saying its board has launched a process to explore and evaluate various strategic alternatives, including a sale of the company, a merger ...